欧洲多发性硬化症治疗市场预测至 2027 年 - 按药物类别(免疫抑制剂和免疫调节剂)、给药途径(注射剂和口服)和分销渠道(医院药房、零售药房和电子商务)划分的 COVID-19 影响和区域分析

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027


No. of Pages: 143    |    Report Code: TIPRE00022634    |    Category: Life Sciences

Europe Multiple Sclerosis Therapeutics Market

市场介绍

多发性硬化症(MS)是一种影响中枢神经系统的自身免疫性疾病。多发性硬化症是一种广泛存在的致残性神经系统疾病,大多数在 20-50 岁年龄段的人群中被诊断出来。这是一种潜在的使人衰弱的疾病,会导致身体的沟通和协调功能中断。

 

市场概况和动态

欧洲多发性硬化症治疗市场预计将从2019年的84.2383亿美元增至2027年的132.8111亿美元;预计 2020 年至 2027 年复合年增长率为 6.0%。市场的增长归因于一些关键驱动因素,例如人们对多发性硬化症的认识不断提高,以及创新产品的开发和推出。然而,多发性硬化症治疗的高成本阻碍了市场的增长。

近年来,人们采取了各种措施和努力来提高人们对神经系统疾病的认识和教育,这有助于患者获得适合此类疾病的药物和治疗。多发性硬化症基金会及其附属团体发起了全国多发性硬化症教育和宣传月,自 2003 年起每年三月举办该活动,以提高对该疾病的认识。该计划的目标是促进对多发性硬化症的了解,并帮助患者就其治疗做出明智的决定。此外,国家 MS 协会创建并启动了“MS Kills Connection” <连接杀死MS”该活动旨在将多发性硬化症患者、治疗多发性硬化症患者的人们以及开展活动以创造一个没有多发性硬化症的世界的人们联系起来。同样,多发性硬化症治疗市场的几家参与者正在开发和推出新产品。地理和制造能力扩张战略以及产品发布有助于公司迎合广泛的客户群。此类新产品的开发和推出正在成为欧洲多发性硬化症治疗市场的主要趋势。

欧洲的 COVID-19 病例数量不断增加。由于第二波 COVID-19 疫情,许多国家政府正在努力加强各公司生产的细胞疗法、基因疗法和再生药物。由于医务人员的多样化以及集中治疗危重患者的决定,不断增加的 COVID-19 病例影响了疾病的诊断和治疗。由于当前的大流行,许多大学和研究机构停止了临床试验,科学家们将重点转移到控制COVID-19疫情上,并努力更好地研究该病毒。因此,对 COVID-19 爆发的日益关注阻碍了市场增长。

 

主要细分市场

欧洲多发性硬化症治疗市场按药物类别分为免疫抑制剂和免疫调节剂。免疫调节剂细分市场在 2019 年占据了较大的市场份额,而免疫抑制剂细分市场预计在预测期内将实现更高的复合年增长率。

欧洲多发性硬化症治疗市场按给药途径分为注射剂和口服剂。注射剂细分市场在 2019 年占据了更大的市场份额,预计该细分市场在预测期内的市场复合年增长率将更高。

基于分销渠道欧洲多发性硬化症治疗市场分为医院药房、零售药房和电子商务。医院药房细分市场在 2019 年占据最大市场份额。然而,预计电子商务细分市场在预测期内的复合年增长率最高。

主要来源和列出的公司

一些与本报告有关的欧洲多发性硬化症治疗市场报告相关的主要和次要来源包括欧洲疾病预防和控制中心 (ECDC) 、欧洲神经病学学会 (EAN) 和欧洲药品管理局 (EMA)。

 

< u>购买报告的理由

  • 根据详细的趋势分析确定潜在的投资领域欧洲 多发性硬化症治疗市场未来几年。
  • < span>深入了解推动支出最高的国家成瘾治疗不同细分市场需求的潜在因素,并确定每个细分市场提供的机会。 span>
  • 加强您对市场需求驱动因素、行业趋势和最新技术发展等方面的了解。
  • 确定推动 欧洲 多发性硬化症治疗市场的主要渠道,提供明确的描绘未来机会,这将有助于分析,从而增加收入。
  • 通过关注不同国家/地区正在开展的项目来引导资源 欧洲 多发性硬化症治疗市场

< span> 

欧洲多发性硬化症治疗市场细分

按药物划分类别

  • 免疫抑制剂
  • 免疫调节剂

按给药途径

  • 注射剂
  • 口服

按分销渠道

  • 医院药房
  • 零售药店
  • 电子商务

按国家/地区

  • 英国
  • 德国
  • 法国
  • 意大利
  • 西班牙
  • 休息欧洲

公司简介

  • 默克公司有限公司
  • 诺华公司
  • 拜耳公司
  • 赛诺菲
  • 百时美施贵宝公司
  • Horizon Therapeutics plc
  • < span>梯瓦制药工业有限公司
  • 武田制药有限公司
  • F.霍夫曼拉罗氏有限公司
  • 百健(Biogen)


Europe Multiple Sclerosis Therapeutics Strategic Insights

Strategic insights for Europe Multiple Sclerosis Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-multiple-sclerosis-therapeutics-market-strategic-framework.webp
Get more information on this report

Europe Multiple Sclerosis Therapeutics Report Scope

Report Attribute Details
Market size in 2019 US$ 8,423.83 Million
Market Size by 2027 US$ 13,281.11 Million
Global CAGR (2020 - 2027) 6.0%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By 药物类别
  • 免疫抑制剂
  • 免疫调节剂
By 给药途径
  • 注射
  • 口服
By 分销渠道
  • 医院药房
  • 零售药房
  • 电子商务
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Horizon Therapeutics plc
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Takeda Pharmaceutical Company Limited
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
  • Get more information on this report

    Europe Multiple Sclerosis Therapeutics Regional Insights

    The regional scope of Europe Multiple Sclerosis Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-multiple-sclerosis-therapeutics-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Multiple Sclerosis Therapeutics Market

    1. Merck & Co., Inc.
    2. Novartis AG
    3. Bayer AG
    4. Sanofi
    5. Bristol-Myers Squibb Company
    6. Horizon Therapeutics plc
    7. TEVA PHARMACEUTICAL INDUSTRIES LTD
    8. Takeda Pharmaceutical Company Limited
    9. F. HOFFMANN-LA ROCHE LTD
    10. Biogen
    Frequently Asked Questions
    How big is the Europe Multiple Sclerosis Therapeutics Market?

    The Europe Multiple Sclerosis Therapeutics Market is valued at US$ 8,423.83 Million in 2019, it is projected to reach US$ 13,281.11 Million by 2027.

    What is the CAGR for Europe Multiple Sclerosis Therapeutics Market by (2020 - 2027)?

    As per our report Europe Multiple Sclerosis Therapeutics Market, the market size is valued at US$ 8,423.83 Million in 2019, projecting it to reach US$ 13,281.11 Million by 2027. This translates to a CAGR of approximately 6.0% during the forecast period.

    What segments are covered in this report?

    The Europe Multiple Sclerosis Therapeutics Market report typically cover these key segments-

  • 药物类别 (免疫抑制剂, 免疫调节剂)
  • 给药途径 (注射, 口服)
  • 分销渠道 (医院药房, 零售药房, 电子商务)
  • What is the historic period, base year, and forecast period taken for Europe Multiple Sclerosis Therapeutics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Multiple Sclerosis Therapeutics Market report:

  • Historic Period : 2017-2018
  • Base Year : 2019
  • Forecast Period : 2020-2027
  • Who are the major players in Europe Multiple Sclerosis Therapeutics Market?

    The Europe Multiple Sclerosis Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Horizon Therapeutics plc
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Takeda Pharmaceutical Company Limited
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
  • Who should buy this report?

    The Europe Multiple Sclerosis Therapeutics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Multiple Sclerosis Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.